Joint Formulary & PAD

Tranylcypromine sulfate - Depression

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Initiation and stabilisation by specialist for a minimum of 6 months before transfer of prescribing to primary care.

Documentation

PAD Profile

ChemicalSubstance :
Tranylcypromine sulfate
Indication :
Depression
Group Name :
Keywords :
MAOIs, monoamine oxidase inhibitors, depressive illness, antidepressants
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Tranylcypromine sulfate is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Depression.

Committee Recommendations (1)

The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed a BLUE (with information sheet) traffic light status for:

·         Phenelzine

·         Isocarboxacid

·         Moclobemide

·         Tranylcypromine

Specialists will initiate and prescribe a minimum of 6 months or until the patient is stable, whichever is longer, prior to transfer of care